RT Journal Article SR Electronic T1 Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.08.01.22277781 DO 10.1101/2022.08.01.22277781 A1 Mona M. Almramhi A1 Chris Finan A1 Catherine S. Storm A1 Amand F. Schmidt A1 Demis A. Kia A1 Rachel Coneys A1 Sandesh Chopade A1 Aroon D. Hingorani A1 Nicholas W. Wood YR 2022 UL http://medrxiv.org/content/early/2022/08/05/2022.08.01.22277781.abstract AB Background There has been considerable interest in statins due to their pleiotropic effects beyond their lipid-lowering properties. Many of these pleiotropic effects are predominantly ascribed to their capacity to inhibit the isoprenylation of Rho small guanosine triphosphatases (Rho GTPases). We aimed to genetically investigate the role of lipids and statin interventions on multiple sclerosis (MS) risk and severity.Method We employed two-sample Mendelian randomization (MR) to: (1) investigate the causal role of lipids (high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG)) levels in MS risk and severity, (2) genetically mimic both cholesterol-dependent (via low-density lipoprotein cholesterol (LDL-C) and cholesterol biosynthesis pathway) and cholesterol-independent (via Rho GTPases) effects of statins on MS risk and MS severity.Results The results of MR using the inverse variance weighted method show that lifelong higher HDL-C (OR 1.14 (95% CI 1.04 to1.26), p-value 7.94E-03) increase MS risk, but LDL-C and TG were not. MR results also show that genetically predicted RAC2 (OR 0.86 (95% CI 0.78 to 0.95), p-value 3.80E-03) is implicated causally in reducing MS risk. Furthermore, we found no evidence for the causal role of lipids and genetically mimicked statins on MS severity. There is no evidence of reverse causation between MS risk and lipids.Conclusions Evidence from this study suggests that HDL-C is a risk factor for MS development. The MR findings suggest that RAC2 (a member of Rho GTPases) is a potent genetic modifier of MS risk. Since RAC2 has been reported to mediate some of the pleiotropic effects of statins, we suggest that statins reduce MS risk via a RAC2-related mechanism(s) (i.e., cholesterol-independent pathway).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) disclosed receipt of the following financial support for the research: M.M.A. is funded by the Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.C.F received additional support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. C.S.S. is funded by Rosetrees Trust, John Black Charitable Foundation and the University College London MBPhD Programme. A.F.S is supported by BHF grant PG/18/503383, and acknowledges support by grant R01 LM010098 from the National Institutes of Health (United States). D.A.K. is supported by an MBPhD Award from the International Journal of Experimental Pathology. R.C. is funded by Eisai, on the Wolfson-Eisai Neurodegeneration University College London PhD programme. N.W.W. is a National Institute for Health Research senior investigator. N.W.W. receives support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All individuals involved in the multiple sclerosis risk and multiple sclerosis severity studies (cases and controls) gave valid informed consent in accordance with approval from the relevant local Ethical Committees or Institutional Review Boards (IRBs). These data are publicly available upon request.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe GWAS summary data used in this article are available at the URLs as follows: Lipid fractions (GLGC) http://csg.sph.umich.edu/willer/public/lipids2013/ ; whole blood cis-eQTL (eQTLgen consortium) https://www.eqtlgen.org/cis-eqtls.html ; whole blood cis-seQTL (GTx consortium) https://www.gtexportal.org/home/datasets ;HDL-C (Neale Lab UK Biobank GWAS) https://docs.google.com/spreadsheets/d/1kvPoupSzsSFBNSztMzl04xMoSC3Kcx3CrjVf4yBmESU/edit#gid=178908679 ; MS risk (discovery) https://imsgc.net/?page_id=31 ; MS severity data is available upon request to the corresponding author of the original publication (Sawcer et al., 2011), Professor Jacob McCauley.